The Promise of CGRP Antibodies to Change Practice in Migraine Treatment

The Promise of CGRP Antibodies to Change Practice in Migraine Treatment
The Promise of CGRP Antibodies to Change Practice in Migraine Treatment
CME, CPE, CNE
Andrew C. Charles, MD; David W. Dodick, MD; Richard B. Lipton, MD
Release Date: July 26, 2018
Expiration Date: July 26, 2019

In this activity, the faculty will cover today’s clinical environment and the challenges associated with the recognition and management of episodic and chronic migraine, and with the effective preventive treatment and prophylaxis of these headache disorders. Dr. Lipton, Dr. Charles, and Dr. Dodick will also highlight the challenges currently encountered by patients and clinicians when implementing preventive treatment for migraine and share the promising new therapies on the horizon and how they compare with currently available therapies. This e-Monograph will include insights and understanding about how these new therapies work, the unique features of the CGRP monoclonal antibodies, how these four new agents have performed in clinical trials and most importantly how they may impact practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Teva Pharmaceuticals.

Begin, Earn CreditView Only, No Credit